key: cord-0792976-txxhj1ci
authors: Pang, J.; Xu, F.; Aondio, G.; Li, Y.; Fumagalli, A.; Lu, M.; Valmadre, G.; Wei, J.; Bian, Y.; Canesi, M.; Damiani, G.; Zhang, Y.; Yu, D.; Chen, J.; Ji, X.; Sui, W.; Wang, B.; Wu, S.; Kovacs, A.; Revera, M.; Wang, H.; Chen, Y.; Cao, Y.
title: Efficacy and tolerability of bevacizumab in patients with severe Covid -19
date: 2020-07-29
journal: nan
DOI: 10.1101/2020.07.26.20159756
sha: 42c1043b009a1a458d390cbbd80604814f673d25
doc_id: 792976
cord_uid: txxhj1ci

On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesized that the anti-VEGF drug bevacizumab might be beneficial for treating Covid-19 patients. We recruited 26 patients from 2-centers (China and Italy) with confirmed severe Covid-19, with respiratory rate [≥]30 times/min, oxygen saturation [≤]93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100mmHg and [≤]300 mmHg, and diffuse pneumonia confirmed by chest radiological imaging. This trial was conducted from Feb 15 to April 5, 2020, and followed up for 28 days. Relative to comparable control patients with severe Covid-19 admitted in the same centers, bevacizumab showed clinical efficacy by improving oxygenation and shortening oxygen-support duration. Among 26 hospitalized patients with severe Covid-19 (median age, 62 years, 20 [77%] males), bevacizumab plus standard care markedly improved the PaO2/FiO2 ratios at days 1 and 7 (elevated values, day 1, 50.5 [4.0,119.0], p<0.001; day 7, 111.0 [85.0,165.0], p<0.001). By day 28, 24 (92%) patients showed improvement in oxygen-support status, 17 (65%) patients were discharged, and none showed worsen oxygen-support status nor died. Significant reduction of lesion areas and ratios were shown in chest CT or X-ray analysis within 7 days. Of 14 patients with fever, body temperature normalized within 72 hours in 13 (93%) patients. Lymphocyte counts in peripheral blood were significantly increased and CRP levels were markedly decreased as shown in available data. Our findings suggested bevacizumab plus standard care was highly beneficial for treating patients with severe Covid-19. Clinical efficacy of bevacizumab warrants double blind, randomized, placebo-controlled trials.

gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, or visceral 10 fistula formation within 6 months before trial enrollment; 8) patients who had 11 undergone major surgery (including preoperative chest biopsy) or received major 12 trauma (such as a fracture) within 28 days before enrollment; patients who might need 13 surgery during the trial; 9) patients with severe, active bleeding such as haemoptysis, Primary outcomes were changes of PaO2/FiO2 at day 1 and day 7. PaO2 was measured 5 by arterial blood gas (ABG) and FiO2 at the time of clinical ABG was obtained. Secondary outcomes included change of chest radiological imaging at day 7, as well 7 as oxygen-support status, discharge rate and change of fever symptom during 28 days 8 follow-up. Oxygen-support status referred to mechanical ventilation, non-invasive 9 ventilation, a transition status of alternate use of non-invasive ventilation and high-10 flow oxygen, high-flow oxygen, low-flow oxygen or ambient air. Chest radiological 11 imaging referred to chest CT or X-ray, which was quantified or semi-quantified by 12 software or team of experts, respectively. Fever was defined as axillary temperature ≥ 13 37.5℃. Co. LTD, Beijing) to obtain the volume and the ratios of the lesions in bilateral lungs. 20 X-ray images were semi-quantified by the Committee of Imaging Experts using the 21 above platform to assess the ratios of the lesions in bilateral lungs. To compare differences between different time points after intervention and baseline 4 point, a paired t-test or Wilcoxon matched-pairs signed-rank test was used for 5 quantitative data. Statuses of oxygen-support and body temperature during 28 days in 6 the bevacizumab-treated population were described with Gantt charts. Safety 7 measurements applied to all patients exposed to bevacizumab. Statistical significance 8 was indicated by a p value of 0.05 and was determined with the use of a two-sided 9 hypothesis test. Wilcoxon signed-rank test and Chi-square test were used to compare 10 the external control and bevacizumab group. All analyses were conducted with SAS 11 software, version 9.4 (SAS Institute, USA). (Table 1) . were shown in chest CT images of these patients. The semi-quantification of chest X-24 ray images showed, the lesion ratios of the right lungs remarkably reduced at day 3 and day 7 compared to baseline (Table 3) . The representative chest CT as well as X-1 ray images were shown in Fig.3 and Fig.4 . Surprisingly, we observed a phenomenon of rapid abatement of fever in 13 of 14 5 febrile patients (93%) within 3 days after bevacizumab treatment regardless of the 6 days of febrile from admission to bevacizumab treatment, which were in a range of 0 7 to 8 days. One trachea intubation patient was an exception with a persistent fever, 8 who had got sepsis that was evidenced by blood and urine bacteria culture (Fig. 5) .

From the available values of laboratory tests at baseline and day 7, the peripheral 10 blood lymphocyte counts and the level of CRP were significantly increased and 11 decreased at day 7, respectively ( Fig. 5 and Table S1 ). (Table 4 ).

For an external comparison cohort, we screened patients with severe Covid-19 who 2 were eligible as control cases admitted during the same period as the bevacizumab-3 treated group in two centers, and 26 external control patients were included as a 1:1 4 ratio to bevacizumab-treated patients. The baseline characteristics were comparable 5 between the two groups (Table 5) . Compared with the control group, bevacizumab These findings indicate that clinical benefits of bevacizumab treatment occur already 11 at early time points (Table 6 ). Compared with the control group, a significantly 12 increased number of patients improved the 28-day oxygen-support status (control, 13 62% vs. bevacizumab, 92%) and the discharge rate (control, 46% vs. bevacizumab, 14 65%) (Fig. S1) severe Covid-19 is completely novel and has not been explored. VEGF treatment was also seen in patients with wet age-related macular degeneration 2 (AMD). 25 VEGF likely significantly contributed to Covid-19-induced inflammation. 3 It is known that VEGF mobilizes inflammatory cells to pathological tissues and anti-4 VEGF would alleviate fever by antagonizing the virus-triggered inflammation. 26,27 At 5 this time of writing, the mechanism underlying increases of lymphocytes is unknown. 6 It is speculated that blocking VEGF by bevacizumab might affect extravasation and 7 redistribution of lymphocytes. As lymphopenia is one of the key pathological changes 8 in contributing to Covid-19 fatality, 28,29 increases of the lymphocytic population 9 would reduce the death rates in severe patients. IQR=interquartile range. One datum was absent at day 7 because of discharge; †Wilcoxon matched-pairs signed-rank test. Reduced platelet counts 4 (31%) 0 (0%) 4 (15%)

Elevated blood urea nitrogen 0 (0%) 2 (14%) 2 (7%)

Skin rash 1 (8%) 0 (0%) 1 (4%)

Local superficial phlebitis 0 (0%) 1 (7%) 1 (4%) Sepsis 1 (8%) 1 (7%) 2 (7%)

Hypertension (grade ≥2) † 2 (15%) 1 (7%) 3 (11%)

Muscle pains in lower extremity 1 (8%) 0 (0%) 1 (4%) Diarrhea 1 (8%) 0 (0%) 1 (4%) Cardiovascular events 1 (8%) 0 (0%) 1 (4%) Hematuria 1 (8%) 0 (0%) 1 (4%) *Adverse events were analyzed for bevacizumab-treated patients whose adverse event information was submitted. †Hypertension of grade ≥2 referred to recurrent or continuous hypertension for more than 24 hours or symptomatic increase in blood pressure by more than 20 mmHg (diastolic) or to more than 150/100 mmHg if the blood pressure was previously within the normal range. Final fever statuses are on the discharge date or at the end of 28-day follow-up. Red color columns indicate the fever status prior to bevacizumab treatment. Orange color marks the fever duration after bevacizumab treatment. Blue color represents postbevacizumab normal body temperature. Diamonds indicate the discharged patients.

Patient numbers match the patient numbers in Fig. 2. B . Lymphocyte counts at day 7 after bevacizumab treatment relative to the baseline (p<0.005). Lymphocyte counts were analyzed from 10 Italian patients and 4 Chinese patients. C. C-reactive protein (CRP) analysed at day 7 compared to the baseline (p<0.02). CRP values were collected from 8 Italian patients and 1 Chinese patient.

World Health Organization. Coronavirus disease (Covid-19) outbreak